Switzerland-based Roche (SIX: RO, ROG) (OTCQX: RHHBY) announced on Friday that the VENTANA PD-L1 (SP263) Assay is offered in counties accepting the CE mark as a companion diagnostic to recognise non-small cell lung cancer (NSCLC) patients eligible for treatment with Libtayo (cemiplimab), a PD-1 inhibitor therapy produced by Regeneron.
The launch of the product is to result in more patients having access to an additional immunotherapy option with Libtayo.
Jill German, Head of Pathology Lab at Roche Diagnostics, said, 'With our companion diagnostics, we can help ensure each patient gets the most appropriate targeted treatment. This approval gives eligible advanced lung cancer patients access to the immunotherapy Libtayo as a first-line treatment. Our high medical value PD-L1 assay portfolio is continuing to help improve access to personalised medicine.'
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review